VIJAYA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | VIJAYA | Market Cap | 11,623 Cr. | Current Price | 1,130 ₹ | High / Low | 1,166 ₹ |
| Stock P/E | 72.8 | Book Value | 82.3 ₹ | Dividend Yield | 0.18 % | ROCE | 20.2 % |
| ROE | 18.1 % | Face Value | 1.00 ₹ | DMA 50 | 996 ₹ | DMA 200 | 994 ₹ |
| Chg in FII Hold | -1.72 % | Chg in DII Hold | 1.33 % | PAT Qtr | 44.2 Cr. | PAT Prev Qtr | 42.7 Cr. |
| RSI | 80.7 | MACD | 44.8 | Volume | 6,00,602 | Avg Vol 1Wk | 3,18,047 |
| Low price | 848 ₹ | High price | 1,166 ₹ | PEG Ratio | 11.0 | Debt to equity | 0.40 |
| 52w Index | 88.7 % | Qtr Profit Var | 31.8 % | EPS | 15.5 ₹ | Industry PE | 34.6 |
📊 Financials: VIJAYA shows decent efficiency with ROCE at 20.2% and ROE at 18.1%, reflecting strong capital utilization. Debt-to-equity ratio of 0.40 is moderate, manageable but higher than low-leverage peers. EPS of ₹15.5 supports profitability, while quarterly PAT grew modestly (₹42.7 Cr → ₹44.2 Cr). Cash flow stability is implied, though earnings growth remains limited.
💹 Valuation: Current P/E of 72.8 is significantly above industry average (34.6), suggesting steep overvaluation. PEG ratio of 11.0 indicates growth is priced expensively. P/B ratio (~13.7) is stretched relative to book value. Dividend yield of 0.18% is negligible, offering little income support.
🏢 Business Model & Advantage: VIJAYA operates in healthcare diagnostics, benefiting from strong demand cycles, brand recognition, and institutional trust. Competitive advantage lies in sector resilience and consistent service demand, though valuations remain a concern.
📈 Entry Zone: Attractive accumulation near ₹950–₹1,000 (close to DMA 200 support). Current price (₹1,130) is near 52-week high (₹1,166), limiting upside potential.
⏳ Long-Term Holding: Suitable for 3–5 year horizon if earnings growth sustains. Partial profit booking advised near ₹1,150–₹1,160 resistance. Long-term holding requires valuation normalization and steady profit expansion.
Positive
- Strong ROCE (20.2%) and ROE (18.1%)
- Moderate debt-to-equity ratio (0.40)
- EPS of ₹15.5 supports profitability
- DII holdings increased (+1.33%), showing domestic confidence
Limitation
- High P/E (72.8 vs industry 34.6)
- PEG ratio of 11.0 indicates expensive growth
- Dividend yield of only 0.18%
- RSI at 80.7 indicates overbought conditions
Company Negative News
- FII holdings decreased (-1.72%), showing reduced foreign investor confidence
- Valuation premium raises risk of correction
Company Positive News
- Quarterly PAT growth (+31.8%)
- DII inflows (+1.33%) reflect strong domestic institutional support
Industry
- Healthcare diagnostics sector trading at PE ~34.6
- VIJAYA trades at a steep premium, reflecting investor optimism
Conclusion
VIJAYA is fundamentally strong with efficient capital metrics and sector resilience, but valuations are stretched. Entry is safer near ₹950–₹1,000, with exits recommended near ₹1,150–₹1,160 resistance. Long-term holding is viable only if earnings growth sustains and valuations normalize.